Workflow
TIAN TU CAPITAL(01973)
icon
Search documents
天图投资(01973) - 海外监管公告 - 深圳市天图投资管理股份有限公司股份质押的公告
2024-10-23 11:50
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並表明概不就因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Tian Tu Capital Co., Ltd. 深圳市天圖投資管理股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1973) 海外監管公告 证券代码:833979 证券简称:天图投资 主办券商:国信证券 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由深圳市天圖投資 管理股份有限公司(「本公司」)作出。 茲載列本公司於全國中小企業股份轉讓系統有限責任公司網站刊登公告如下,僅供 參閱。 承董事會命 深圳市天圖投資管理股份有限公司 董事長兼執行董事 王永華先生 中國深圳 2024年10月23日 截至本公告日期,本公司董事會成員包括執行董事王永華先生、馮衛東先生、鄒雲 麗女士及李小毅先生;非執行董事黎瀾先生及代永波先生;及獨立非執行董事王世 林先生、刁揚先生及蔡洌先生。 公告编号:2024-080 深圳市天图投资管理股份有限公司 股份质押的公告 本公司及董事会全体成员保证公 ...
天图投资(01973) - 根据上市规则第13.17条作出之披露
2024-10-23 11:00
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Tian Tu Capital Co., Ltd. 深圳市天圖投資管理股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1973) 根據上市規則第13.17條作出之披露 本公告乃由深圳市天圖投資管理股份有限公司(「本公司」,連同其附屬公司統稱「本 集團」)根據香港聯合交易所有限公司證券上市規則(「上市規則」)第13.17條作出。 於2022年5月5日,本公司發行了本金金額分別為人民幣200百萬元(簡稱:22天圖 01)和人民幣300百萬元(簡稱:22天圖02,連同22天圖01統稱「2022年公司債券(第 一期)」)的兩筆公司債券。該兩筆公司債券的票面利率分別為每年4.27%(於發行滿 二週年時調整為3.50%)和每年4.99%(將於發行滿三週年時調整),預計分別於2025 年5月5日及2027年5月5日到期。2022年公司債券(第一期)由深圳市深擔增信融資擔 保有限公司(「深圳擔保」 ...
天图投资(01973) - 2024 - 中期财报
2024-09-30 09:17
Asset Management - As of June 30, 2024, the total assets under management reached RMB 21.1 billion, with RMB 16.2 billion contributed by funds and RMB 4.9 billion from direct investments[6]. - The company manages 13 RMB funds and 3 USD funds, with external fund investors contributing 81.3% of the total committed capital[6]. - The total committed capital for the consolidated funds was RMB 14.8 billion, with RMB 2.8 billion contributed by the company's own funds[7]. - The company’s funds have a total of 16 funds, with 8 consolidated funds and 8 non-consolidated funds[7]. - The company has exited or partially exited investments in 73 portfolio companies as of June 30, 2024[10]. - The average fair value change for the top 5% of selected portfolio companies was RMB 655.6 million[10]. - The company’s investments cover various vertical markets, including beauty and health, food and beverage, ESG-driven technology, and biotechnology[10]. Financial Performance - Revenue decreased from RMB 23,366 million in the first half of 2023 to RMB 21,479 million in the first half of 2024, representing a decline of approximately 8.1%[14]. - The net investment loss for the first half of 2024 was RMB (619,607) million, compared to RMB (226,291) million in the same period of 2023, indicating a significant increase in losses[14]. - The company's total income and net investment loss amounted to RMB (598,128) million in the first half of 2024, compared to RMB (202,925) million in the first half of 2023[14]. - The company's pre-tax loss for the first half of 2024 was RMB (840,005) million, compared to RMB (200,379) million in the same period of 2023[14]. - The company's loss for the six months ended June 30, 2023, was approximately RMB 189.6 million, while the loss for the six months ended June 30, 2024, was RMB 742.2 million[26]. - The basic loss per share for the period was RMB (1.07), compared to RMB (0.37) in the same period last year, indicating increased losses per share[75]. - The company reported a net loss of RMB 740,511 thousand for the six months ended June 30, 2024, compared to a loss of RMB 194,045 thousand for the same period in 2023, indicating a significant increase in losses[78]. Cash Flow and Liquidity - The company's cash and cash equivalents decreased from RMB 1,117,230 million as of December 31, 2023, to RMB 1,023,471 million as of June 30, 2024[15]. - Operating cash flow for the six months ended June 30, 2024, was RMB 231,173 thousand, a substantial increase from RMB 108,362 thousand in the same period of 2023, representing a growth of about 113%[79]. - The company reported a net cash outflow from investing activities of RMB 82,276 thousand for the six months ended June 30, 2024, compared to RMB 98,809 thousand in the same period of 2023, indicating a reduction in cash used for investments[80]. - The company’s financing activities resulted in a net cash outflow of RMB 243,453 thousand for the first half of 2024, compared to RMB 133,154 thousand in the same period of 2023, reflecting increased financing costs[80]. Shareholder Information - Mr. Wang holds 209,748,220 unlisted shares, representing approximately 40.35% of the relevant share class and 30.27% of the total share capital[48]. - The company has a significant shareholder, Paladin Capital Management, with 78,264,498 unlisted shares, representing 15.06% of the relevant share class and 11.29% of the total share capital[51]. - The overall ownership structure indicates a concentrated shareholding with key stakeholders holding substantial percentages of the total share capital[51]. - The company has not proposed an interim dividend for the six months ending June 30, 2024[66]. - There were no declared or proposed final dividends for the six months ended June 30, 2024[10]. Investment Activities - The company made minority equity investments totaling approximately RMB 105 million in seven early-stage private companies during the first half of 2024[10]. - In the first half of 2024, the company achieved an investment return of approximately RMB 1,077.5 million through methods such as IPOs, equity transfers, buybacks, and dividends[11]. - The company plans to explore different financial instruments, such as convertible bonds and mezzanine capital, to enhance operational flexibility and returns amid industry downturns[13]. - The company aims to expand its coverage into evolving lifestyle-related investment areas, including biotechnology and next-generation information technology[13]. Compliance and Governance - The audit committee has confirmed that the interim results comply with applicable accounting principles and have been adequately disclosed[68]. - The company emphasizes compliance with the Corporate Governance Code as per the listing rules[164]. - The company has adopted a securities trading code for directors and senior management, ensuring compliance during the reporting period[67]. Future Plans - The company plans to utilize the unutilized net proceeds based on the revised purposes to be approved at the special general meeting on July 26, 2024[62]. - The company plans to invest RMB 593.2 million in fund management operations, with RMB 256.5 million already utilized and RMB 336.7 million remaining, expected to be used by the end of 2025[63]. - The company plans to invest RMB 95.1 million in debt repayment and capital structure optimization, with RMB 92.5 million utilized and RMB 2.6 million remaining, expected to be used by the end of 2024[63].
天图投资(01973) - 2024 - 中期业绩
2024-08-30 08:56
Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 21,479,000, a decrease of 8.1% compared to RMB 23,366,000 for the same period in 2023[2] - Net investment loss for the period was RMB (619,607,000), compared to RMB (226,291,000) in the previous year, reflecting a significant increase in losses[2] - Total revenue and investment income or loss decreased from a loss of RMB 202.9 million for the six months ended June 30, 2023, to a loss of RMB 598.1 million for the six months ended June 30, 2024[12] - The company's loss before tax increased from RMB 200.4 million for the six months ended June 30, 2023, to RMB 840.0 million for the six months ended June 30, 2024[19] - The company had a net loss attributable to owners of the company of RMB (740,511) million for the six months ended June 30, 2024, compared to RMB (194,045) million in the same period of the previous year[25] - The company reported a basic loss per share of RMB (1.07) for the six months ended June 30, 2024, compared to RMB (0.37) in the same period of 2023, indicating a decline in shareholder value[25] Investment and Assets - Total assets under management as of June 30, 2024, amounted to RMB 21.1 billion, with RMB 16.2 billion contributed by funds and RMB 4.9 billion from direct investments[3] - The average internal rate of return for the funds managed was 8.1% as of June 30, 2024[3] - As of June 30, 2024, the company managed investments in 187 existing portfolio companies, with 73 investments fully or partially exited[5] - The total assets less current liabilities amounted to RMB 14,127,884 million as of June 30, 2024, down from RMB 16,146,554 million at the end of 2023[27] Operational Expenses - Other operating expenses increased from RMB 14.6 million for the six months ended June 30, 2023, to RMB 28.8 million for the six months ended June 30, 2024, due to higher investment management-related consulting expenses[14] - Employee costs for the six months ended June 30, 2024, were RMB (27,262) million, slightly down from RMB (27,500) million in the previous year, indicating stable payroll expenses[24] Cash Flow and Debt - Cash and cash equivalents decreased from RMB 1,117.2 million as of December 31, 2023, to RMB 1,023.5 million as of June 30, 2024, primarily due to repayment of bank loans[20] - Total debt decreased from RMB 1,272.9 million as of December 31, 2023, to RMB 1,027.2 million as of June 30, 2024, mainly due to settlement of pre-received equity transfer payments[21] Tax and Deferred Assets - The company recorded a tax credit of RMB 97.8 million for the six months ended June 30, 2024, compared to RMB 10.7 million for the six months ended June 30, 2023, due to a decrease in deferred tax liabilities[18] - The deferred tax assets recognized for the six months ended June 30, 2024, amounted to RMB 108,788,000, compared to RMB 14,279,000 for the same period in 2023[33] Strategic Plans and Governance - The company plans to explore alternative financial instruments to enhance operational flexibility and returns amid market challenges[8] - The company aims to expand its investment coverage into evolving lifestyle-related sectors, including biotechnology and next-generation information technology[8] - The company remains committed to optimizing operational capabilities and maintaining robust risk management and corporate governance[8] - The company approved the 2024 H-share incentive plan on June 28, 2024, aimed at recognizing contributions and attracting talent[23] - The company has adopted a securities trading code for directors and senior management, ensuring compliance during the reporting period[43] Market and Foreign Exchange Risks - The company faced foreign exchange risks primarily due to its operations in mainland China and did not hedge against currency fluctuations[23] - The company did not enter into any foreign exchange forward contracts or other hedging contracts as of June 30, 2024[42] Shareholder Information - The company did not propose an interim dividend for the six months ended June 30, 2024[39] - The company proposed a final dividend of RMB 2 per share for the year ended December 31, 2022, totaling approximately RMB 103,955,000, which was approved by shareholders[34] Audit and Compliance - The audit committee has reviewed the interim results and confirmed compliance with applicable accounting principles and standards[44] - The independent auditor has conducted a review of the interim financial information in accordance with international auditing standards[45] Company Structure and Management - The board of directors includes executive directors Wang Yonghua, Feng Weidong, Zou Yunli, and Li Xiaoyi, along with non-executive directors Li Lan and Dai Yongbo, and independent non-executive directors Wang Shilin, Diao Yang, and Cai Lian[50] - Shenzhen Tian Tu Investment Management Co., Ltd. was established on July 25, 2017, as a limited partnership in China[50] - The company is focused on investments in small and micro enterprises[50] - The company operates under the regulations of the Hong Kong Stock Exchange[50] - The management team is dedicated to sharing insights and collaborating with stakeholders[50]
天图投资(01973) - 2023 - 年度财报
2024-04-30 09:27
Financial Performance - In 2023, the company faced a net loss of approximately RMB 870 million due to significant valuation adjustments in its investment portfolio[22]. - Total revenue for 2023 was RMB 44,614,000, a decrease of 3% from RMB 45,983,000 in 2022[36]. - Net investment loss for 2023 was RMB (813,704,000), compared to a gain of RMB 377,234,000 in 2022[36]. - Total income and net investment loss amounted to RMB (769,090,000) in 2023, down from RMB 423,217,000 in 2022[36]. - The company reported a pre-tax loss of RMB (959,882,000) for 2023, compared to a profit of RMB 159,481,000 in 2022[36]. - The total comprehensive loss for the year amounted to RMB (839,581,000), compared to a comprehensive income of RMB 748,678,000 in the previous year[200]. - The company recognized an impairment loss of RMB (28,314,000) under the expected credit loss model, compared to RMB (44,000) in the previous year[200]. - The foreign exchange difference from overseas operations resulted in a gain of RMB 36,106,000, down from RMB 215,765,000 in 2022[200]. Investment Activities - The company successfully launched five new RMB funds in 2023, raising approximately RMB 1.16 billion in new capital[23]. - The company invested in nine portfolio companies in 2023, focusing on enhancing investments in biomedicine and technology sectors[23]. - Investment capital for 2023 amounted to RMB 464.4 million, with exit amounts and dividend returns totaling RMB 432.6 million[17]. - The company achieved an exit capital of approximately RMB 432.6 million through various methods including IPOs and share transfers in 2023[34]. - Approximately 30% of the portfolio companies achieved a year-on-year revenue growth of over 30% in the first three quarters of 2023, indicating resilience despite market challenges[26]. - The company invested approximately RMB 464.4 million in nine portfolio companies in 2023, with about 45.1% allocated to consumer enterprises in sectors like service robots, healthcare, and environmental technology[32]. Assets and Liabilities - Total assets under management reached RMB 24.4 billion, with a compound annual growth rate of 16.5% from 2015 to 2023[15]. - As of December 31, 2023, the total assets under management amounted to RMB 24.4 billion, with funds contributing approximately RMB 19.2 billion and direct investments contributing about RMB 5.2 billion[27]. - The company’s total liabilities decreased to RMB 8,820,714,000 in 2023 from RMB 9,791,999,000 in 2022[38]. - The debt-to-asset ratio as of December 31, 2023, was 56.20%, down from 58.26% as of December 31, 2022[64]. - The net cash balance increased to RMB 1,117,230,000 in 2023 from RMB 613,612,000 in 2022[37]. Corporate Governance - The company has adopted a corporate governance code to enhance shareholder value and accountability, effective from October 6, 2023, when its H shares were listed on the Stock Exchange[89]. - The board consists of four executive directors, two non-executive directors, and three independent non-executive directors, ensuring a diverse governance structure[91]. - The company emphasizes the importance of a balanced board composition to meet business requirements and enhance governance standards[104]. - The company has implemented a mechanism to maintain the independence of the board and conducts annual assessments of this independence[93]. - The company has established an internal control system to mitigate risks and enhance risk management levels[113]. Risk Management - The company is focused on enhancing its risk management capabilities and ensuring compliance with regulatory standards[81]. - The board has established a comprehensive risk management and internal control system, ensuring compliance with corporate governance codes[111]. - The risk management process includes five steps: risk identification, assessment, analysis, control, and reporting[112]. - The company maintains a zero-tolerance policy towards bribery and corruption, providing 92 hours of anti-corruption training to directors and employees in 2023[116]. Employee and Management - The total salary cost for employees in 2023 was RMB 61.2 million, relatively stable compared to RMB 61.4 million in 2022[72]. - The company has a total of 87 employees as of December 31, 2023[72]. - The management team includes experienced individuals with over 28 years and 20 years in the investment industry, respectively[73][74]. - The management team is committed to maintaining high standards of corporate governance and oversight of executive performance[82]. Shareholder Relations - The company emphasizes effective communication with shareholders to enhance investor relations and ensure timely information disclosure[127]. - The company has established a dedicated investor relations section on its website for public access to communication documents and reports[127]. - Shareholders holding more than 10% of the company's shares can request the Board to convene an extraordinary general meeting[123]. - The company currently has no dividend policy in place and will regularly review its performance to determine if dividends are appropriate[128]. Market Outlook - The company plans to continue exploring investment opportunities despite uncertainties in the macroeconomic environment in 2024[24]. - The company plans to explore market-oriented investment strategies that do not rely on IPO exits in 2024[35]. - The company aims to consolidate its leading position in the Chinese consumer sector while expanding into selected investment areas such as biomedicine[35].
天图投资(01973) - 2023 - 年度业绩
2024-03-28 12:52
Financial Performance - For the year ended December 31, 2023, the company reported a revenue of RMB 44.614 million, a decrease of 44.8% compared to RMB 45.983 million in 2022[2] - The net loss from continuing operations for the year was RMB 875.687 million, compared to a profit of RMB 532.913 million in 2022[2] - Total revenue decreased from RMB 459.83 million in 2022 to RMB 446.14 million in 2023, a decline of approximately 3.7%[9] - Investment income turned from a profit of RMB 377.23 million in 2022 to a loss of RMB 813.70 million in 2023, primarily due to unrealized fair value changes of financial assets[10] - Total income and investment income net amount shifted from a profit of RMB 423.22 million in 2022 to a loss of RMB 769.09 million in 2023[11] - Other operating expenses increased from RMB 506.21 million in 2022 to RMB 707.40 million in 2023, reflecting higher investment management-related consulting expenses[14] - Financial costs significantly decreased from RMB 1.187 billion in 2022 to RMB 696.4 million in 2023, mainly due to a reduction in bond liabilities[15] - Other income rose from RMB 84.15 million in 2022 to RMB 200.30 million in 2023, driven by increased government subsidies and interest income[16] - Share of profits from associates and joint ventures improved from a loss of RMB 29.21 million in 2022 to a profit of RMB 19.0 million in 2023[17] - The company recorded a tax credit of RMB 84.2 million in 2023, compared to a tax expense of RMB 107.3 million in 2022[18] - Loss from continuing operations for 2023 was approximately RMB 875.69 million, compared to a profit of RMB 52.16 million in 2022[19] - The net investment loss for 2023 was RMB (813,704) thousand, compared to a gain of RMB 377,234 thousand in 2022, indicating a significant decline in investment performance[27] - The company reported a pre-tax loss of RMB (959,882) thousand for 2023, compared to a pre-tax profit of RMB 159,481 thousand in 2022[27] - The net loss attributable to the owners of the company for 2023 was RMB (872,962,000), compared to a profit of RMB 559,285,000 in 2022, indicating a significant decline[38] Assets and Investments - The total assets under management as of December 31, 2023, amounted to RMB 24.4 billion, with RMB 19.2 billion contributed by funds and RMB 5.2 billion from direct investments[4] - The average internal rate of return for the company's funds as of December 31, 2023, was 11.3%[4] - The company invested approximately RMB 464.4 million in nine portfolio companies in 2023, with 45.1% allocated to consumer enterprises in service robotics, healthcare, and environmental technology[7] - The company realized approximately RMB 432.6 million in exit funds through IPOs, equity transfers, buybacks, and dividends in 2023[7] - External capital accounted for 81.3% of the total committed capital in the managed funds, while the company contributed 18.7% of its own funds[4] - The Hang Seng Index fell nearly 14% in 2023, impacting the fair value of the company's private equity investments[3] - The company established a new investment fund, TianTu XingQin Venture Capital Fund, with an investment of RMB 216.0 million, focusing on the consumer sector[24] Cash Flow and Debt - Cash and cash equivalents increased from RMB 613.6 million at the end of 2022 to RMB 1.117 billion at the end of 2023, attributed to net proceeds from global offerings and project exits[21] - As of December 31, 2023, the company's total debt decreased from RMB 1,283.9 million to RMB 1,272.9 million, primarily due to the repayment of bank loans amounting to RMB 15.2 million[22] - The company's net current assets increased to RMB 1,310,431,000 in 2023 from RMB 999,154,000 in 2022, representing a growth of approximately 31.1%[30] - Total assets minus current liabilities decreased to RMB 16,146,554,000 in 2023 from RMB 17,119,099,000 in 2022, a decline of about 5.7%[30] Shareholder and Dividend Information - The company proposed a final dividend of RMB 2 per share for the year ended December 31, 2022, totaling approximately RMB 103,955,000, which was approved by shareholders[37] - The company did not declare a final dividend for the year ending December 31, 2023, indicating a shift in dividend policy[37] - The weighted average number of ordinary shares used to calculate basic loss per share increased to 561,070,000 in 2023 from 519,773,000 in 2022, an increase of about 7.9%[38] Compliance and Governance - The company has maintained compliance with the corporate governance code since its listing on October 6, 2023[49] - The audit committee consists of three directors, with Mr. Cai Lian serving as the chairman, ensuring compliance with listing rules and corporate governance codes[52] - The group's consolidated financial statements for the year ended December 31, 2023, have been reviewed and agreed upon by Deloitte, aligning with the amounts approved by the board on March 28, 2024[53] - The company appointed Deloitte as its international auditor during the special general meeting held on January 19, 2024, with no significant post-reporting period events disclosed[54] - The financial reports are prepared in accordance with applicable accounting standards, rules, and regulations, ensuring appropriate disclosures[53] Operational Highlights - The company launched five new RMB funds in 2023, including a fund focused on the biopharmaceutical sector[4] - Approximately 30% of the portfolio companies achieved a revenue growth of over 30% year-on-year in the first three quarters of 2023[3] - The company has established a comprehensive internal control and risk management system, which is monitored by the audit committee[52] - The company expresses gratitude to all employees, shareholders, clients, banks, and business partners for their trust and support[56] - The annual general meeting is scheduled for May 23, 2024, as per the company's articles of association[57] - The company was officially listed on the Hong Kong Stock Exchange on October 6, 2023, marking its initial public offering[58] Accounts Receivable and Liabilities - Accounts receivable from private equity fund management services decreased from RMB 44,030,000 in 2022 to RMB 29,148,000 in 2023, representing a decline of approximately 33.7%[40] - The aging analysis of accounts receivable shows that RMB 1,616,000 is due within one year, while RMB 27,532,000 is overdue by more than three years as of December 31, 2023[42] - The company has no significant contingent liabilities as of December 31, 2023, indicating a stable liability position[23] - Deferred tax liabilities decreased to RMB 119,087,000 in 2023 from RMB 200,549,000 in 2022, a reduction of approximately 40.6%[30] - The company's equity attributable to owners remained relatively stable at RMB 7,301,778,000 in 2023 compared to RMB 7,296,538,000 in 2022, showing minimal change[30] - The company did not recommend the distribution of a final dividend for the reporting period[44] Use of Proceeds - The net proceeds from the global offering amounted to approximately HKD 1,008.5 million (equivalent to RMB 925.4 million) after deducting underwriting fees and related expenses[46] - The planned use of net proceeds includes 65% for private fund management business, 25% for direct investment business, and 10% for general corporate purposes[47] - As of December 31, 2023, approximately RMB 389.6 million of the net proceeds has been utilized, with the remaining funds held in short-term or current deposits[48]